Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

A new influenza A drug from Jiankangyuan, requiring only one dose! It has entered Phase III clinical trials, and the raw materials will be produced in Macun District!

Published Time:

2023-11-14

On the morning of November 9th, Jiankangyuan, in collaboration with Jiaozuo No. 2 People's Hospital, held a launch meeting for a Phase III clinical trial of a new influenza drug. Attendees included leaders from Jiaozuo Municipal Health Commission, Macun District, and the hospital, as well as Dr. Jin Fang, Chief Scientist of Jiankangyuan. The group's Phase III clinical trial of TG-1000, a Class I innovative chemical drug for the treatment of influenza, has already begun with 50 participating hospitals, and the project is rapidly entering the enrollment phase. This drug is used to treat patients aged 12 and above with uncomplicated influenza A and B. After TG-1000 is launched, its raw materials will be produced in the high-end raw material project in Macun District, playing an important role in extending, supplementing, and strengthening the biopharmaceutical industry in the district.

 

In recent years, Macun District has focused on the development advantages of the biopharmaceutical industry, using Jiankangyuan as the leader. Macun District plans to build a biopharmaceutical base, fully undertaking the Shenzhen Jiankangyuan industrial transfer project, extending the pharmaceutical manufacturing industry chain, and striving to create a biopharmaceutical industrial park with a total investment of 5.5 billion yuan and an area of 80 hectares. At the same time, it focuses on building a biopharmaceutical R&D platform driven by leading enterprises, guided by technological innovation, and supported by advantageous products, promoting the implementation of projects such as the Jiankangyuan Biopharmaceutical Research Institute and the Raw Material Research Center, and developing into an innovative highland for the high-quality development of Jiaozuo's biopharmaceutical industry. To date, the district's biopharmaceutical industry has an annual output value of nearly 2 billion yuan.

 Picture

Influenza (flu) is a contagious respiratory illness caused by influenza viruses. Currently, influenza remains one of the world's most serious public health challenges. According to Dr. Jin Fang, Chief Scientist of Joincare Pharmaceutical Group Industry Co., Ltd., TG-1000 is a prodrug that is converted into the active ingredient TG-0527 through esterase hydrolysis. It inhibits influenza virus polymerase acidic protein endonuclease, thereby inhibiting viral RNA synthesis. It is easy to use and has the advantage of requiring only one dose for a cure.

 

Source: WeChat Official Account "Charm Macun"